Neil M. Iyengar, MD

home / authors / neil-m-iyengar-md

Articles

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Neil M. Iyengar, MD;Sarah Sammons, MD, Duke Cancer Institute;Gabriel Hortobagyi, MD, MACP, FASCO

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Neil M. Iyengar, MD;Gabriel Hortobagyi, MD, MACP, FASCO

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Neil M. Iyengar, MD;Gabriel Hortobagyi, MD, MACP, FASCO

October 25th 2021

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

Frontline Treatment Approaches for HR+/HER2- MBC

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Sarah Sammons, MD, Duke Cancer Institute;Neil M. Iyengar, MD

October 18th 2021

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

HR+ MBC: Prognostic Factors and Treatment Planning

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Gabriel Hortobagyi, MD, MACP, FASCO;Neil M. Iyengar, MD;Sarah Sammons, MD, Duke Cancer Institute

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Gabriel Hortobagyi, MD, MACP, FASCO;Neil M. Iyengar, MD;Sarah Sammons, MD, Duke Cancer Institute

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

<1 2